Tevogen Bio (TVGN.US) experiences a 38% premarket surge on its expanded AI partnership with Microsoft.

According to Zhitong Finance, Tevogen Bio (TVGN) announced on Friday that it has expanded its collaboration with Microsoft (MSFT.US) focused on artificial intelligence and its PredicTcell technology. As of the time of writing, the clinical-stage biotechnology company's stock rose nearly 38% to $1.86 before the market opened on Monday. PredicTcell is Tevogen Bio's patented technology for predicting precise T-cell targeting.

Based on the successful trial results of TVGN489, Tevogen Bio aims to use machine learning to perform key simulations to accelerate the identification of new targets. The company stated that by leveraging Microsoft's artificial intelligence, it can analyze large datasets of the entire genome faster and more accurately. Tevogen Bio is also actively researching potential treatments for human papillomavirus.